|
ATG3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.89848137210902E-14 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.62929694577952E-12 |
| Normal-vs-Stage2 |
3.58420000012849E-07 |
| Normal-vs-Stage3 |
1.70086167372574E-12 |
| Normal-vs-Stage4 |
1.54040113997667E-11 |
| Stage1-vs-Stage2 |
8.348000E-01 |
| Stage1-vs-Stage3 |
4.525600E-02 |
| Stage1-vs-Stage4 |
2.354500E-02 |
| Stage2-vs-Stage3 |
2.480000E-01 |
| Stage2-vs-Stage4 |
1.075810E-01 |
| Stage3-vs-Stage4 |
5.023000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.66133814775094E-16 |
| Normal-vs-AfricanAmerican |
8.352800E-04 |
| Normal-vs-Asian |
2.75480000000439E-06 |
| Caucasian-vs-AfricanAmerican |
2.264400E-01 |
| Caucasian-vs-Asian |
6.633700E-02 |
| AfricanAmerican-vs-Asian |
8.886200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.64834812466097E-12 |
| Normal-vs-Female |
1.89070981093664E-13 |
| Male-vs-Female |
1.817220E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.64109845105054E-11 |
| Normal-vs-Age(41-60Yrs) |
1.65734093116043E-12 |
| Normal-vs-Age(61-80Yrs) |
5.7092108818324E-12 |
| Normal-vs-Age(81-100Yrs) |
1.187500E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.106400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.236400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.392400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.656800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.519600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.972800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.033800E-01 |
| Classical-VS-Follicular |
3.456800E-01 |
| Classical-VS-Other |
2.051800E-01 |
| Classical-VS-Normal |
3.44613226843649E-13 |
| Tall-VS-Follicular |
9.192100E-02 |
| Tall-VS-Other |
5.929600E-01 |
| Tall-VS-Normal |
1.5922999585527E-09 |
| Follicular-VS-Other |
2.427800E-01 |
| Follicular-VS-Normal |
1.72970000000827E-06 |
| Other-VS-Normal |
1.483850E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.03395070283341E-12 |
| Normal-vs-N1 |
1.68109970388741E-10 |
| N0-vs-N1 |
3.454100E-02 |
|
|
